In fact, the oral ERK1/2 phosphorylation inhibitor MK-8353, which has a similar mechanism to the ERK1/2 phosphorylation inhibitor SCH772984, has shown some promising results in clinical studies of cancer patients [28], implies a new choice for patients with AHSA1 overexpression. The gene discussed is MAPK3; the disease is cancer.